Parkinson’s can be diagnosed by analysing compounds found on the skin, a study has found, paving the way for easier testing using quick and painless skin swabs.
Experts led from Manchester found that both the onset of the degenerative brain condition and the nature of its progression can be determined by studying sebum.
This is the oily, waxy substance that coats and protects the skin of mammals like us and is secreted out of the hair follicles.
Those with Parkinson’s are known to produce excess sebum — a condition known as ‘seborrhoea’ — but is remains a lesser-studied fluid in the diagnosis of the disease.
A new test for Parkinson’s is welcome, according to experts from Parkinson’s UK.
Onset of the disease can be subtle and doctors currently rely on both symptom assessment and scans for the loss of dopamine-producing cells.
Yet similar cell losses can also arise as a result of other neurological conditions, as can characteristic symptoms like tremors, slowness, stiffness and balance issues.
In fact, a recent poll by Parkinson’s UK of 2,000 people with the disease revealed that more than a quarter were initially misdiagnosed with a different condition.
This led to almost half of these patients receiving treatments for a condition they did not have — including medication and, in some cases, even surgical operations.
Parkinson’s can be diagnosed by analysing compounds found on the skin, a study has found — paving the way for easier testing using quick and painless skin swabs, like pictured
‘We believe that our results are an extremely encouraging step towards tests that could be used to help diagnose and monitor Parkinson’s,’ said paper author and mass spectrometry expert Perdita Barran of the University of Manchester.
‘Not only is the test quick, simple and painless but it should also be extremely cost-effective because it uses existing technology that is already widely available.
‘We are now looking to take our findings forwards to refine the test to improve accuracy even further and to take steps towards making this a test that can be used in the NHS.’
The investigation was inspired by Joy Milne who — after her husband was diagnosed with Parkinson’s at the age of 45 — was found to possess a remarkable ability to detect the onset of the disease in others using her sense of smell.
In their studies, Professor Barran and colleagues took samples of sebum from an initial cohort of 500 participants, some of whom had Parkinson’s disease.
Analysing these samples using different mass spectrometry techniques, the researchers were able to identify 10 different chemical compounds in sebum that appeared in greater or decreased amounts in people with Parkinson’s.
And by analysing the concentrations of these compounds, the team found that they could predict whether someone had the debilitating condition with an accuracy rate of 85 per cent.
The researchers went on to validate their findings in a larger cohort of people from both the Netherlands and the United Kingdom.
In a second study, the team used high-resolution mass spectrometry to profile the complex chemical signature for Parkinson’s found in people’s sebum and show that it is possible to track subtle but significant changes as the disease progresses.
Specifically, the team found that those with the condition undergo detectable changes in lipid (fat) processing and function of mitochondria — the cellular ‘batteries’ that are known to malfunction in people with Parkinson’s.
These findings show that swab tests would also be able to track how the condition is progressing after Parkinson’s diagnosis, as well as providing a means to evaluate the efficacy of future experimental treatments to halt or reverse the disease.
‘Not only is the test quick, simple and painless but it should also be extremely cost-effective because it uses existing technology that is already widely available,’ said paper author and mass spectrometry expert Perdita Barran of the University of Manchester
Parkinson’s disease affects one in 500 people, including about 145,000 individuals in the UK. It causes muscle stiffness, slowness of movement, tremors, sleep disturbance, chronic fatigue, an impaired quality of life and can lead to severe disability
Parkinson’s UK’s associate director of research, David Dexter, said that the research could lead to swab tests that would ‘revolutionise the way we diagnose Parkinson’s’.
‘Every hour, two more people in the UK are diagnosed with Parkinson’s and a significant portion of these people may well have been misdiagnosed with, and treated for, another condition before receiving their correct diagnosis,’ he added.
‘This has been compounded in the COVID-19 pandemic where people have been left waiting and have faced months of anxiety to confirm their diagnosis by a health professional.’
‘However, with this innovative test, we could see people being diagnosed quickly and accurately enabling them to access vital treatment and support to manage their Parkinson’s symptoms sooner.’
In a second study, the team used high-resolution mass spectrometry to profile the complex chemical signature for Parkinson’s found in people’s sebum and show that it is possible to track subtle but significant changes as the disease progresses
With their initial studies complete, the researchers are now looking to further develop their swab-based Parkinson’s test, as well as exploring the potential to use it to ‘stratify’ patients by the severity of the disease’s progression.
Alongside plans to commercialise the tests, the researchers are also investigating whether a similar approach could be applied to the detection of other conditions — including COVID-19.
The full findings of the two studies were published in the journals ACS Central Science and Nature Communications.